Company profilePharmaceutical#11 of 1,318 in Pakistan10 DRAP alerts

Werrick Pharmaceuticals Pakistan

Pharmaceutical company · 421 brands · 354 molecules

Ranked #11 of 70 companies in Cardiac Care

421 registered products 113 pharmaceutical brands 354 distinct molecules 10 DRAP alerts

Company overview

421
registered products
113
pharmaceutical brands
354
distinct molecules
12
therapeutic classes
10
DRAP alerts

Werrick Pharmaceuticals Pakistan is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 421 product registrations across 354 distinct molecules. It is the 11th largest registrant in Pakistan by product count, and ranks 11th of 70 in Cardiac Care. Its portfolio is concentrated in Cardiac Care and Angiotensin-Ii Antagonists, Combinations. DRAP has issued 10 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Werrick

261 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

210
ceilings with an approval date
1
not revised in 2+ years
2024
oldest approval year
20241
2025206
20263
Longest without revision

Top molecules by brand count

Amlodipine14 brands
Quetiapine12 brands
Risperidone10 brands
Rifampicin9 brands
Thiamine9 brands
Amoxycillin8 brands
Pyridoxine8 brands

Therapeutic classes

Cardiac Care · 10Angiotensin-Ii Antagonists, Combinations · 5Neuro · 5Antidepressants · 5Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 4Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 4Ace Inhibitor · 4Quinolone Antibacterials · 4Lipid Modifying Agents · 4Gastro · 3Drugs For Obstructive Airway Diseases, Systemic · 3Other Calcium Supplements · 3

Conditions treated

Hypertension · 7Ulcer/Reflux/Flatulence/Acidity · 3Anxiety/Depression/Insomnia · 2Cold/Cough/Flu · 2High Cholestrol · 2Schizophrenia/Psychosis · 2Epilepsy/Convulsion · 1Asthma/Allergy · 1Heart Failure · 1Non-Sedative Agents · 1Oral Agents · 1Conventional Agents · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official395 products · Rs 23.52 – Rs 87,982.91
DVAGO47 products · Rs 14.96 – Rs 510
Servaid48 products · Rs 57 – Rs 1,350
Median across source: Rs 204.3

Regulatory record

10 alerts in the DRAP feed we track.

National Pharmacovigilance Cell (NPC), DRAP released a revised draft of Guidelines on Nati
2026-07-06
Recall Alert: Lipidem® / Lipoplus® Emulsion for Infusion (Product Stability Risk)
2025-09-17
Rapid Alert: PRESENCE OF FALSIFIED INJECTION RHOPHYLAC 300MCG, HUMAN ANTI-D IMMUNOGLOBULIN
2025-04-30
Rapid Alert: Falsified Dayquil Kids (Vicks) Berry Cold & Cough + Mucus Purportedly Manufac
2024-12-03
Rapid Alert: Falsified Rhophylac 300mcg PFS, Human Anti-D Immunoglobulin Injection Identif
2024-11-07
National Pharmacovigilance Cell (NPC), DRAP released draft Guidelines on National Pharmaco
2024-09-15
Rapid Alert; Drug Product: Unregistered and Falsified Immune globulin Products (Hyp-Rho-D
2023-09-23
Suspected Falsified Alert; Drug Products; Suspected Anti-D Immunoglobulin Injection in the
2022-10-31

Competitive set

Companies whose registered portfolio overlaps most with this one.

WILSONS PHARMACEUTICALS126 shared molecules
SCOTMANN PHARMACEUTICALS107 shared molecules
SEARLE PAKISTAN (PVT.) LTD.106 shared molecules
HILTON PHARMA (PVT) LIMITED97 shared molecules
BIO LABS (PVT) LTD.94 shared molecules
HIGH - Q INTERNATIONAL92 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

WILSONS PHARMACEUTICALS holds 39 molecules not in this portfolio
AcefyllineAlbuterolBenazeprilBetamethasoneCaffeineCaffiene
GETZ PHARMA PAKISTAN (PVT) LTD. holds 204 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcyclovirAdrenalineAlbendazoleAmitriptyline
SCOTMANN PHARMACEUTICALS holds 56 molecules not in this portfolio
AmilorideAminophyllineAmmonium ChlorideAmoxicillin BaseAnastrazoleApixaban

Get the full profile for Werrick

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.